Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.

Share this

Director of Biology Operations, Kathy Dodgson, is delighted to take part in the event on Thursday 13 October 2022 and will sit on the panel to consider and discuss 'De-risking Oncology Drug Discovery for Targeted Degradation'.

The panel will review how assay development and reagent selection can influence go- and no-go decisions prior to advancing a TPD or RNAi candidate into the clinic.
They will also discuss the challenges, strategies and best practices when it comes to confident results interpretation of efficacy and safety of drug candidates.

You can find out more about the event here.

Discover how Charnwood Molecular's expert bioscience team can support your drug discovery projects here.